Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has designated Progenics Pharmaceuticals' PRO 140 a fast track product for the treatment of HIV infection.
Subscribe to our email newsletter
The fast track development program facilitates development and expedites regulatory review of drugs intended to address an unmet medical need for serious or life-threatening conditions.
PRO 140 belongs to a new class of HIV/AIDS therapeutics – viral-entry inhibitors – that are intended to protect healthy cells from viral infection. PRO 140, currently in phase Ib clinical trials in HIV-infected individuals, is a humanized monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter cells.
“Fast track status has the potential to accelerate the development of PRO 140,” said Dr Paul Maddon, Progenics’ chief science officer. “Although great strides have been made in HIV treatment, there is an urgent need for the development of new therapies such as PRO 140 to address the limitations of currently available HIV drugs.”
With fast track designation for PRO 140, Progenics can take advantage of several programs at the FDA to streamline the regulatory review process and to work more closely with the agency on product development plans.